Seeking Alpha
 

Orexigen Therapeutics, Inc. (OREX)

- NASDAQ
  • Wed, Feb. 25, 12:24 PM
    • Orexigen Therapeutics (OREX +0.7%) Q4 results ($M): Revenues: 23.0 (+999%); Operating Income: 2.4 (+111.4%); Net Income: 0.6 (+102.8%); EPS: 0.00 (+100.0%).
    • Contrave sales in U.S. by Takeda: $6.5M; royalties to OREX: $1.3M. Global sales: $12.3M.
    | 2 Comments
  • Wed, Feb. 25, 6:32 AM
    • Orexigen Therapeutics (NASDAQ:OREX): Q4 EPS of $0.00 misses by $0.21.
    • Revenue of $22.95M (+2568.6% Y/Y) misses by $26.7M.
    • Press Release
    | Comment!
  • Nov. 10, 2014, 11:16 AM
    • Orexigen Therapeutics (OREX +21%) Q3 results: Revenues: $30.9M (+999%); R&D Expense: $10.7M (-17.7%); G&A: $7.1M (+10.9%); Operating Income: $13M (+169.9%); Net Income: $11.3M (+160.8%); EPS: $0.09 (+147.4%); Quick Assets: $118.6M (-33.0%).
    • No guidance given.
    | 1 Comment
  • Nov. 10, 2014, 7:08 AM
    • Orexigen Therapeutics (NASDAQ:OREX): Q3 EPS of $0.09 beats by $0.22.
    • Revenue of $30.86M vs. $0.9M prior.
    • Press Release
    | Comment!
  • Aug. 7, 2014, 9:28 AM
    • Orexigen Therapeutics (NASDAQ:OREX) Q2 results: Revenue: $857K (unch); Operating Expenses: $23.7M (+23.7%); Operating Loss: ($22.8M) (-24.6%); Net Loss: ($24.5M) (-34.6%); Loss Per Share: ($0.21) (-10.5%); Quick Assets: $133.3M (-24.7%).
    • No guidance given.
    | Comment!
  • Aug. 7, 2014, 7:29 AM
    • Orexigen Therapeutics (NASDAQ:OREX): Q2 EPS of -$0.21 in-line.
    • Revenue of $857K (flat Y/Y).
    • Press Release
    | Comment!
  • May. 8, 2014, 5:09 PM
    • Orexigen Therapeutics (OREX): revenues: $857K (unch); operating expenses: $24M (+16.5%); loss/share: ($0.23) (-9.5%); quick assets: $155.1M (-12.4%).
    • NB32 PDUFA date: June 10, 2014.
    | 1 Comment
  • Mar. 12, 2014, 4:51 PM
    • Orexigen Therapeutics (OREX): Q4 EPS of -$0.21 misses by $0.02.
    • Revenue of $857K
    • Press Release
    | Comment!
  • Nov. 12, 2013, 6:34 AM
    • Orexigen Therapeutics (OREX): Q3 EPS of -$0.19 misses by $0.01.
    • Revenue of $857K misses by $33K. (PR)
    | Comment!
  • May. 8, 2013, 6:43 PM
    Orexigen (OREX): Q1 EPS of -$0.21 beats by $0.13. Revenue of $857K misses by $33.K. (PR)
    | Comment!
  • Mar. 14, 2013, 3:30 PM
    Shares of Orexigen (OREX -4.8%) slip deeper into the red today after it reported a Q4 that beat on a per share basis, but came up short on revenue. The company reported a loss of $0.41 per share, versus the consensus of a $0.44 per share loss. Revenues were $857K, below analyst estimates of $890K. Total operating expenses were significantly higher for the quarter, coming in at $33.3M compared to $5.2M in Q411, reflecting higher R&D expenses associated with the conduct of its Contrave cardiovascular outcomes trial. Read more on earnings here: Earnings Call Transcript.
    | 1 Comment
  • May. 9, 2011, 7:12 AM
    Orexigen (OREX) reports a quarterly loss of $0.24 vs. an expected -$0.21, but is still hopeful about obesity drug Contrave : "we have been preparing for a meeting with FDA to discuss a viable path forward for Contrave... [and] have submitted to the Agency a specific, innovative, and robust proposal to assess cardiovascular risk..." (PR)
    | Comment!
Visit Seeking Alpha's
OREX vs. ETF Alternatives
Company Description
Orexigen Therapeutics Inc is a biopharmaceutical company. The Company is engaged in development of pharmaceutical product candidates for the treatment of obesity. Its product candidate includes NB32 and Empatic.